Banque Pictet & Cie SA Sells 83,130 Shares of Abbott Laboratories $ABT

Banque Pictet & Cie SA trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 37.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 139,532 shares of the healthcare product maker’s stock after selling 83,130 shares during the quarter. Banque Pictet & Cie SA’s holdings in Abbott Laboratories were worth $17,482,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Linden Thomas Advisory Services LLC raised its stake in Abbott Laboratories by 0.9% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 46,409 shares of the healthcare product maker’s stock valued at $5,815,000 after purchasing an additional 397 shares in the last quarter. Compagnie Lombard Odier SCmA acquired a new stake in Abbott Laboratories during the fourth quarter worth about $84,578,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Abbott Laboratories by 15.3% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 36,127 shares of the healthcare product maker’s stock worth $4,526,000 after buying an additional 4,782 shares in the last quarter. Powerhouse Assets LLC bought a new position in Abbott Laboratories in the 4th quarter valued at about $225,000. Finally, Victory Financial Group LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $272,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock opened at $102.41 on Thursday. The stock has a market cap of $178.36 billion, a price-to-earnings ratio of 27.53, a P/E/G ratio of 1.64 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The company has a 50 day simple moving average of $109.68 and a 200 day simple moving average of $121.44. Abbott Laboratories has a 1 year low of $100.88 and a 1 year high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Elizabeth C. Cushman sold 263 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the transaction, the executive vice president owned 38,573 shares of the company’s stock, valued at $4,458,267.34. This represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock worth $353,097 over the last three months. 0.46% of the stock is owned by corporate insiders.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott joined a $575M funding round for wearable maker Whoop as a strategic investor, positioning ABT to participate in consumer health/wearables and personalized‑health data opportunities that could broaden diagnostics and subscription revenue pathways. Abbott joins $575M funding round for wearable maker Whoop
• Positive Sentiment: Abbott integrated its Precision Oncology testing portfolio into Flatiron’s OncoEMR, improving workflow for oncology providers and potentially raising test ordering and revenue capture in oncology diagnostics. Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
• Positive Sentiment: Analyst optimism: Seeking Alpha noted a rating upgrade into Q1 earnings, suggesting some analysts see improving fundamentals and an attractive entry point after recent weakness. Upgrades can help limit downside and attract value buyers. Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade)
• Neutral Sentiment: Analyst commentaries and comparisons (GEHC vs ABT and sector roundups) are driving attention but not a clear consensus; some authors highlight valuation appeal while noting macro and currency risks. GEHC or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Investor guides and sector lists name Abbott among steady healthcare picks for long‑term growth (dividend history, nutrition and Libre growth cited), supporting longer‑term investor interest even if near‑term volatility persists. Best Healthcare Stocks to Buy Right Now for Long-Term Growth
• Negative Sentiment: Analyst actions and comments are mixed: BTIG cut its price target (though maintained a Buy), signaling revised near‑term expectations; downward PT moves can pressure the stock. BTIG lowers price target on Abbott
• Negative Sentiment: Market concern about a recent soft quarter and a revenue miss (and the stock’s slide from its 52‑week high) is keeping selling pressure; near‑term headwinds include currency and macro uncertainty. This Dividend King Is Down 26%. When Will It Bounce Back?
• Negative Sentiment: Short‑term price action: coverage noting recent daily dips and lower trading volume versus average suggests current momentum is weak despite the strategic positives. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Daiwa Securities Group reduced their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. BTIG Research lowered their price objective on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating for the company in a research report on Tuesday. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Finally, Citigroup lowered their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $135.68.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.